Summary

Your HFE H63D result determines whether you carry the milder of the two common hereditary hemochromatosis variants — on its own H63D rarely causes clinical iron overload, but when combined with C282Y (compound heterozygote) it meaningfully increases iron accumulation risk, making your C282Y status the critical companion finding.

Genotype spectrum

CC (His/His — normal)

Your iron absorption regulation at this locus is fully intact. Combined with normal C282Y status, your HFE system works as designed.

CG (His/Asp — carrier)

You absorb iron slightly more efficiently than CC individuals. For anyone at risk of iron deficiency — athletes, vegetarians, menstruating women — this is a genuine mild advantage.

GG (Asp/Asp — homozygous)

Interventions are simple and effective if iron does trend high — you respond well to dietary modification and occasional blood donation. Most H63D homozygotes never need any clinical intervention.

Practical takeaway

For GG Carriers (H63D Homozygous)

Monitoring:
• Ferritin and transferrin saturation every 1-2 years. This is monitoring, not emergency action.
• If ferritin consistently above 300 ng/mL (men) or 200 ng/mL (women): increase to annual monitoring and consider blood donation.
• If transferrin saturation consistently >45%: discuss with GP.

Dietary:
• Avoid unnecessary iron supplements. Most multivitamins containing iron are fine — you don't need extra standalone iron.
• No need to restrict red meat or modify cooking implements. Your iron absorption increase is mild.
• If ferritin runs high: tea or coffee with meals mildly reduces iron absorption (tannin effect).

What "normal" looks like for you:
• Ferritin in upper-normal range (100-200 ng/mL for men, 50-150 ng/mL for women) is expected and not concerning.
• Only act if ferritin exceeds the thresholds above on repeated testing.

Expected response: If blood donation is needed, ferritin drops ~30-50 ng/mL per donation. Most H63D homozygotes who donate 1-2x/year maintain normal ferritin indefinitely.
For CG Carriers (H63D Heterozygous)

Without C282Y:
• Periodic ferritin check (every 2-3 years) is reasonable but not urgent.
• No dietary modifications needed.
• Your mild iron absorption advantage works in your favour if you're an athlete, vegetarian, or menstruating.

With C282Y heterozygous (compound heterozygote C282Y/H63D):
• This is the clinically important scenario. See Compound Modifiers.
• Ferritin every 1-2 years. Closer monitoring if trending upward.
• Avoid unnecessary iron supplements.
• Blood donation if ferritin exceeds 300 ng/mL (men) or 200 ng/mL (women).
• Most compound heterozygotes never need therapeutic phlebotomy — but a small percentage do.
For CC Carriers (Normal at H63D)
• No iron-related concern from this locus.
• Your C282Y status is the only HFE finding that matters for you.
• Standard iron guidance applies.

Evidence detail

What This Gene Does

HFE produces the protein that regulates how much iron your gut absorbs by controlling hepcidin — the master iron-regulating hormone. The H63D mutation (histidine → aspartic acid at position 63) partially impairs this regulation, but far less dramatically than the C282Y mutation. H63D reduces HFE's ability to interact with the transferrin receptor, which blunts the hepcidin signalling cascade — but unlike C282Y, the protein still reaches the cell surface and retains partial function.

Think of it this way: if C282Y removes the brake on iron absorption entirely, H63D loosens the brake cable. The brake still works, just not quite as well.

Mechanism

The iron regulation system relevant to H63D works through the same pathway as C282Y (see hfe_c282y for the full mechanism), but with a crucial difference in severity:

1. Normal HFE sits on the cell surface and interacts with transferrin receptor 1 (TfR1). When transferrin saturation is high (lots of iron circulating), HFE detects this and signals the liver to produce hepcidin, which reduces iron absorption.
2. C282Y prevents HFE from reaching the cell surface entirely (misfolded protein retained in ER). Complete loss of this regulatory arm.
3. H63D allows HFE to reach the cell surface but reduces its binding affinity for TfR1. The regulatory system still works — just with reduced sensitivity. The hepcidin response is blunted, not absent.

This is why H63D alone is clinically mild. The iron sensing system is degraded, not broken. Hepcidin still responds to iron status, just with a higher threshold. In most people, this mild impairment never exceeds the body's compensatory capacity.

Why compound heterozygosity matters:

When you have one C282Y allele (one completely non-functional HFE copy) AND one H63D allele (one partially functional HFE copy), you have no fully functional HFE. Your best copy is the H63D variant — working, but impaired. This is meaningfully worse than either mutation alone as a carrier, because a C282Y carrier at least has one completely normal HFE copy, and an H63D carrier also has one normal copy. The compound heterozygote has zero normal copies.

However, because the H63D copy retains partial function, the compound heterozygote phenotype is much milder than C282Y homozygosity (where both copies are completely non-functional).

HFE H63D

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (9)